Biohit Oyj

Share Issue/Capital Change • Sep 12, 2014

Disclosure 317717

Biohit Oyj - Total number of voting rights and capital

Biohit Oyj B-shares Subscribed with Stock Options II 2013

Biohit Oyj Stock Exchange Release September 12, 2014 at 9:30 a.m. (EEST Biohit Oyj B-shares Subscribed with Stock Options II 2013 Biohit Oyj Stock Exchange Release September 12, 2014 at 9:30 a.m. (EEST)A total number of 45,000 new Biohit Oyj B-shares have been subscribed for with stock options II 2013 during August 8 - 13, 2014. These shares have been entered into the trade register on September 12, 2014, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ OMX Helsinki as of September 15, 2014 together with the existing B-shares. The share subscription price was EUR 2.2766 per share with stock options II 2013. The entire subscription price of EUR 102,447 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value. After the subscription the number of all Biohit Oyj's shares will rise into 14,030,593 shares (13,985,593) and B-shares will rise into 11,055,093 shares (11,010,093). The new shares will correspond to a percentage of 0.3% of Biohit Oyj's total number of shares and 0.06% of the voting rights after registration. The share subscription period with stock options II 2013 began on July 1, 2013 and will end June 30, 2015. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at www.biohithealthcare.com. Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is “Innovating for Health” - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com